An Open-label Extension Study to Compare the Long-term Efficacy, Safety, Immunogenicity and Pharmacokinetics of FKB327 and Humira® in Patients With Rheumatoid Arthritis on Concomitant Methotrexate
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 13 Oct 2017
At a glance
- Drugs Adalimumab (Primary)
- Indications Rheumatoid arthritis
- Focus Adverse reactions
- Acronyms ARABESC-OLE
- Sponsors Fujifilm Kyowa Kirin Biologics
- 10 Jun 2017 Biomarkers information updated
- 18 Jul 2016 Status changed from recruiting to active, no longer recruiting.
- 25 Nov 2015 Planned number of patients changed from 600 to 544 as reported by ClinicalTrials.gov.